Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Br J Cancer
; 130(1): 53-62, 2024 01.
Article
in En
| MEDLINE
| ID: mdl-37980367
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phenylthiohydantoin
/
Pyrazines
/
Triazoles
/
Benzamides
/
Prostatic Neoplasms, Castration-Resistant
Limits:
Humans
/
Male
Language:
En
Journal:
Br J Cancer
Year:
2024
Document type:
Article
Affiliation country:
Estados Unidos
Country of publication:
Reino Unido